Introduction
Methods
Subjects and setting
Statistical methods
Results
Demographics and clinical characteristics
Co-morbidity
Variable | COVID-19 Positive | COVID-19 Negative | p-value |
---|---|---|---|
Number of Patients | 43 | 668 | |
Overall previous diseases | 27 (62.79%) | 156 (23.35%) | < 0.0001 |
Stroke | 1 (2.33%) | 2 (0.3%) | 0.1709 |
Myocardial Infarction | 2 (4.65%) | 9 (1.35%) | 0.1390 |
Chronic Heart Disease | 1 (2.33%) | 23 (3.4%) | 1.0000 |
Inflammatory Bowel Disease | 0 | 8 (1.2%) | 1.0000 |
Rheumatological Disorder | 1 (2.33%) | 14 (2.10%) | 0.6115 |
Transplantation | 0 | 3 (0.45%) | 1.0000 |
Kidney Disease | 4 (9.30%) | 3 (0.45%) | 0.0004 |
Dialysis | 0 | 0 | n.a. |
Autoimmune Liver Disease | 0 | 1 (0.15%) | 1.0000 |
Liver Cirrhosis | 1 (2.33%) | 2 (0.30%) | 0.1709 |
Lung Disease | 5 (11.63%) | 72 (10.78%) | 0.8010 |
Lupus | 0 | 2 (0.30%) | 1.0000 |
Hypertension | 4 (9.30%) | 34 (5.1%) | 0.2787 |
Endocrine disorder | 2 (4.65%) | 28 (4.2%) | 0.7017 |
Diabetes | 1 (2.33%) | 21 (3.1%) | 1.0000 |
Allergic disorders | 1 (2.33%) | 33 (4.9%) | 0.7146 |
Other | 4 (9.30%) | 69 (10.3%) | 1.0000 |
Clinical presentation
Variable | COVID-19 Positive | COVID-19 Negative | p-value |
---|---|---|---|
Number of Patients | 43 | 668 | |
Fever (> 37.5 °C) | 22 (51.16%) | 214 32.04%) | < 0.0001 |
Gustatory Dysfunction | 27 (62.79%) | 156 (23.35%) | < 0.0001 |
Olfactory Dysfunction | 25 (58.14%) | 133 (19.91%) | < 0.0001 |
Visual Dysfunction | 5 (11.63%) | 80 (11.98%) | 0.8454 |
Auditory Dysfunction | 2 (4.65%) | 55 (8.23%) | 0.4569 |
Sensibility Dysfunction | 11 (25.58%) | 87 (13.02%) | 0.1353 |
Dyspnoea | 21 (48.84%) | 267 (39.97%) | 0.0254 |
Fatigue | 39 (90.70%) | 466 (69.76%) | 0.0001 |
Headache | 34 (79.07%) | 419 (62.72%) | 0.0073 |
Joint Pain | 26 (60.47%) | 309 (46.26%) | 0.0015 |
Rhinorrhea | 28 (52.69%) | 352 (52.69%) | 0.0197 |
Cough | 32 (74.42%) | 378 (56.59%) | 0.0004 |
Pharyngitis | 26 (60.47%) | 360 (53.89%) | 0.0981 |
Diarrhea | 14 (32.56%) | 177 (26.50%) | 0.8507 |
Ocular Pruritus | 18 41.86%) | 211 (31.59%) | 0.4021 |
Scrotal Pain | 0 | 13 (4.39%) | 0.7031 |
Duration in days | |||
---|---|---|---|
Symptom | Symptoms in COVID-19 positive patients (days) | Symptoms in COVID-19 negative patients (days) | p-value |
Fever (> 37.5 °C) | 3.5 (n = 22) | 2 (n = 214) | 0.0004 |
Olfactory Dysfunction | 6 (n = 25) | 3 (n = 133) | 0.0010 |
Visual Dysfunction | 2 (n = 5) | 2.5 (n = 80) | 0.6739 |
Auditory Dysfunction | 1 (n = 2) | 3 (n = 55) | 0.1734 |
Sensibility Dysfunction | 2 (n = 11) | 2 (n = 87) | 0.1670 |
Dyspnoea | 5.5 (n = 21) | 3 (n = 267) | 0.0355 |
Fatigue | 5 (n = 39) | 3 (n = 466) | 0.0010 |
Headache | 3 (n = 34) | 3 (n = 419) | 0.0567 |
Cough | 4.5 (n = 32) | 3 (n = 378) | 0.1737 |
Pharyngitis | 3.5 (n = 26) | 3 (n = 360) | 0.0411 |
Diarrhea | 2 (n = 14) | 2 (n = 177) | 0.4913 |
Olfactory and gustatory dysfunction symptoms
Variable | COVID-19 Positive | COVID-19 Negative | p-value |
---|---|---|---|
General disturbance in taste | 27 (62.79%) | 149 (22.31%) | 0.0001 |
No taste of sweet | 3 (6.98%) | 18 (2.69%) | 0.1280 |
No taste of sour | 3 (6.98%) | 15 (2.25%) | 0.0890 |
Only bitter taste | 2 (4.65%) | 12 (1.80%) | 0.2054 |
Taste diminished | 20 (46.51%) | 95 (14.22%) | 0.0001 |
Metallic taste | 2 (4.65%) | 34 (5.09%) | 1.0000 |
Other taste disturbance | 4 (9.30%) | 18 (2.69%) | 0.0382 |
Mean number of changes in taste | 0.8 | 0.3 | 0.0001 |
Variable | COVID-19 Positive | COVID-19 Negative | p-value |
---|---|---|---|
Use of anti-inflammatory medication | 26 (60.4%) | 245 (36.68%) | 0.0019 |
Ibuprofen | 11 (25.6%) | 137 (20.5%) | 0.4271 |
Acetaminophen | 13 (30.2%) | 90 (13.5%) | 0.0025 |
Aspirin | 1 (2.3%) | 25 (3.7%) | 1.0000 |
Metamizole | 6 (14.0%) | 21 (3.1%) | 0.0039 |
Diclofenac | 1 (2.3%) | 1 (0.1%) | 0.1174 |
Other medication | 2 (4.7%) | 29 (4.3%) | 0.0027 |
Variable | COVID-19 Negative with OGD | COVID-19 Negative without OGD | p-value |
---|---|---|---|
Number of Patients | 184 | 484 | |
Fever (37.5 °C) | 80 (43.48%) | 134 (27.69%) | 0.0104 |
Visual Dysfunction | 39 (21.20%) | 41 (8.47%) | 0.0001 |
Auditory Dysfunction | 37 (20.11%) | 18 (3.72%) | 0.0001 |
Sensibility Dysfunction | 38 (20.65%) | 49 (10.12%) | 0.0001 |
Dyspnoea | 114 (61.96%) | 153 (31.61%) | 0.0001 |
Fatigue | 165 (89.67%) | 301 (62.19%) | 0.0001 |
Headache | 153 (83.15%) | 266 (54.96%) | 0.0001 |
Joint Pain | 132 (71.74%) | 177 (36.57%) | 0.0001 |
Rhinorrhea | 132 (71.74%) | 220 (45.45%) | 0.0001 |
Cough | 139 (75.54%) | 239 (49.38%) | 0.0001 |
Pharyngitis | 140 (76.09%) | 220 (45.45%) | 0.0001 |
Diarrhea | 77 (41.85%) | 100 (20.66%) | 0.0001 |
Ocular Pruritus | 71 (38.59%) | 140 (28.93%) | 0.0176 |
Medication | |||
General use of medication | 82 (44.57%) | 163 (33.68%) | 0.0091 |
Ibuprofen | 45 (24.46%) | 92 (19.01%) | 0.1192 |
Acetaminophen | 31 (16.85%) | 59 (12.19%) | 0.1152 |
Aspirin | 9 (4.89%) | 16 (3.31%) | 0.3348 |
Metamizole | 12 (6.5%) | 9 (1.86%) | 0.0020 |
Diclofenac | 1 (0.54%) | 0 | 0.2754 |
Ketoprofen | 1 (0.54%) | 0 | 0.2754 |
Other medication | 11 (5.98%) | 18 (3.72%) | 0.2005 |
Pre-existent diseases in COVID-19 negative tested patients with olfactory and gustatory dysfunction (binary scaled) | |||
Pre-existent disease | 109 (59.24%) | 322 (66.53%) | 0.0314 |
Stroke | 0 | 2 (0.41%) | 1.0000 |
Myocardial Infarction | 4 (2.17%) | 5 (1.03%) | 0.2690 |
Chronic heart disease | 8 (4.35%) | 15 (3.10%) | 0.4291 |
Rheumatological disease | 7 (3.80%) | 7 (1.45%) | 0.0706 |
Transplantation | 0 | 3 (0.62%) | 0.5651 |
Kidney disease | 2 (1.09%) | 1 (0.21%) | 0.1854 |
Dialysis | 0 | 0 | n.a |
Autoimmune liver disease | 0 | 1 (0.21%) | 1.0000 |
Liver cirrhosis | 1 (0.54%) | 1 (0.21%) | 0.4753 |
Lung disease | 23 (12.50%) | 49 (10.12%) | 0.3763 |
Lupus | 0 | 2 (0.41%) | 1.0000 |
other | 52 (28.26%) | 108 (22.31%) | 0.1077 |